Centenial Surgical Suture Limited (CSURGSU) Fair Value & Analysis
Healthcare · IN · Market cap ₹292M
Fair value as of: Jul 5, 2026
From 14 valuation models · updated today
Share price −7.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹73.04 – ₹166.00 · fair‑value band ₹22.01 – ₹34.71 · the ₹80.00 price screens above the ₹22.01 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Centenial Surgical Suture Limited (CSURGSU) currently trades at ₹80.00, while our model-based Fair Value estimate is ₹22.01 — implying the stock looks roughly 72.5% overvalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Centenial Surgical Suture Limited generated revenue of ₹538M at a net margin of -4.1%. Revenue declined 5.4% year over year. It earns a return on equity of -7.4%. Net debt stands at ₹105M. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹22.01 (bear case) to ₹34.71 (bull case); at ₹80.00, the current price sits above that range. The share trades about 58% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside — at -72%, CSURGSU screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Centenial Surgical Suture Limited engages in the development, manufacturing, and supply of surgical sutures and other medical devices in India and internationally. The company offers absorbable sutures, such as natural and synthetic sutures; and non-absorbable sutures comprising needles for cardiovascular surgery, monofilament polyamide atraumatic needle suture combinations, braided silk atraumatic needle suture combinations, monofilament stainless steel wire, and temporary pacemaker electrodes. It also provides female urinary incontinency sets, titanium hemostatic clips for cardiovascular surgery, non-absorbable synthetic knotted surgical meshes, disposable aortic punches for cardiovascular anastomosis, disposable skin stapler maniplers, and cardiovascular vessel knives for cardiovascular surgery. The company was founded in 1995 and is based in Thane, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Centenial Surgical Suture Limited reported revenue of ₹538M in FY2026 versus ₹444M in FY2022, a compound +4.9%/yr. Reported net income was −₹22.0M in FY2026.
Is CSURGSU fairly valued? → Check now
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $412.02 | $165.35 | -60% |
| EssilorLuxottica Société anonyme ESLOF | $190.25 | $125.65 | -34% |
| HOYA Corporation HOCPY | $168.16 | $96.16 | -43% |
| Medline Inc MDLN | $34.71 | $30.15 | -13% |
| Becton, Dickinson and Company BDX | $149.56 | $117.04 | -22% |
| Alcon Inc ALC | $66.58 | $36.99 | -44% |
| ResMed Inc R1MD34 | R$260.00 | R$32.27 | -88% |
| West Pharmaceutical Services, Inc WST | $330.92 | $114.00 | -66% |
| Terumo Corporation TRUMF | $14.62 | $12.65 | -13% |
| Straumann Holding SAUHY | $13.07 | $5.51 | -58% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Centenial Surgical Suture Limited (CSURGSU) undervalued?
What is the fair value of CSURGSU?
What is the quality score of CSURGSU?
What is the revenue of Centenial Surgical Suture Limited (CSURGSU)?
What is the net profit margin of CSURGSU?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.